Free Trial Information
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...year.Pharmas including Bristol Myers Squibb Co. (NYSE:BMY) and Novo Nordisk A/S...
Read More
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...amyloid, with the latest coming Wednesday from Novo Nordisk...
...Brand), NN2211 (Compound #), liraglutide (Generic), Victoza (Other) Novo Nordisk A/S AB...
Read More
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...rare bleeding disordersNovo Seeds is funding Hemab ApS, which emerged with an exclusive license from Novo Nordisk A/S...
...Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB Leerink Arch Venture Partners Temasek Lightstone Ventures UCB Ventures GV Novo Holdings Novo Nordisk A/S Genmab...
Read More
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...to be completed next quarter, with a commercial launch in 2H21.Novo Nordisk Foundation spins out incubatorThe Novo Nordisk...
Read More
BioCentury | Nov 6, 2020
Deals

With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

...used in a product crucial to its future, while also buying out that drug’s royalty stream.Novo Nordisk A/S (CSE:NOVO...
...Stephen Hansen contributed to this report.TARGETSGLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Paul Bonanos Rybelsus, oral semaglutide (NN9924, OG217SC) Novo Nordisk A/S Emisphere...
Read More
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...amylin/GLP-1 combo By stephen hansen, associate editor Novo Nordisk...
...for the even-greater efficacy the combo could produce. Novo Nordisk A/S...
...that mimics gastric bypass surgery.” Mads Thomsen, Novo Nordisk...
Read More
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...to allocate more capital to venture investments.Novo Holdings is the umbrella investment organization for the Novo Nordisk...
...focused on private and public venture investments. Novo Holdings is also the controlling shareholder of Novo Nordisk A/S...
Read More
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...candidate is under EMA review. Novo’s growth hormone deficiency drug gains FDA approvalFDA approved Sogroya somapacitan from Novo Nordisk A/S...
...Programmed cell death 1 ligand 1 Virginia Li AbbVie Inc. AstraZeneca plc the National Academy of Science FDA Bristol Myers Squibb Co. Novo Nordisk...
Read More
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...team includes two C-level executives with a history of entering deals around cardiovascular programs with Novo Nordisk A/S (CSE:NOVO...
Read More
BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...a request for comment from BioCentury.Evotec, Novo pair up to tackle kidney diseaseEvotec SE (Xetra:EVT) and Novo Nordisk A/S...
...E epsilon 4 Paul Bonanos ALZ-801, blu8499, NRM8499, NRM-8499 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Alzheon Inc. Merck & Co. Inc. LumiraDx Ltd. NIH Evotec SE Novo Nordisk A/S covid-19 cov19dx cov19count cov19count...
Read More
Items per page:
1 - 10 of 1741
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...year.Pharmas including Bristol Myers Squibb Co. (NYSE:BMY) and Novo Nordisk A/S...
Read More
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...amyloid, with the latest coming Wednesday from Novo Nordisk...
...Brand), NN2211 (Compound #), liraglutide (Generic), Victoza (Other) Novo Nordisk A/S AB...
Read More
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...rare bleeding disordersNovo Seeds is funding Hemab ApS, which emerged with an exclusive license from Novo Nordisk A/S...
...Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB Leerink Arch Venture Partners Temasek Lightstone Ventures UCB Ventures GV Novo Holdings Novo Nordisk A/S Genmab...
Read More
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...to be completed next quarter, with a commercial launch in 2H21.Novo Nordisk Foundation spins out incubatorThe Novo Nordisk...
Read More
BioCentury | Nov 6, 2020
Deals

With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

...used in a product crucial to its future, while also buying out that drug’s royalty stream.Novo Nordisk A/S (CSE:NOVO...
...Stephen Hansen contributed to this report.TARGETSGLP-1R (GLP1R) - Glucagon-like peptide-1 receptor Paul Bonanos Rybelsus, oral semaglutide (NN9924, OG217SC) Novo Nordisk A/S Emisphere...
Read More
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...amylin/GLP-1 combo By stephen hansen, associate editor Novo Nordisk...
...for the even-greater efficacy the combo could produce. Novo Nordisk A/S...
...that mimics gastric bypass surgery.” Mads Thomsen, Novo Nordisk...
Read More
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...to allocate more capital to venture investments.Novo Holdings is the umbrella investment organization for the Novo Nordisk...
...focused on private and public venture investments. Novo Holdings is also the controlling shareholder of Novo Nordisk A/S...
Read More
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...candidate is under EMA review. Novo’s growth hormone deficiency drug gains FDA approvalFDA approved Sogroya somapacitan from Novo Nordisk A/S...
...Programmed cell death 1 ligand 1 Virginia Li AbbVie Inc. AstraZeneca plc the National Academy of Science FDA Bristol Myers Squibb Co. Novo Nordisk...
Read More
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...team includes two C-level executives with a history of entering deals around cardiovascular programs with Novo Nordisk A/S (CSE:NOVO...
Read More
BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...a request for comment from BioCentury.Evotec, Novo pair up to tackle kidney diseaseEvotec SE (Xetra:EVT) and Novo Nordisk A/S...
...E epsilon 4 Paul Bonanos ALZ-801, blu8499, NRM8499, NRM-8499 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Alzheon Inc. Merck & Co. Inc. LumiraDx Ltd. NIH Evotec SE Novo Nordisk A/S covid-19 cov19dx cov19count cov19count...
Read More
Items per page:
1 - 10 of 1741